Search
Mimopezil
go.drugbank.com/drugs/DB05520ExperimentalMimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.
Synonyms: N-(2-Hydroxy-3-methoxy-5-chlorobenzylidene)huperzine AQR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder … QR-333 has been investigated as a treatment for diabetic peripheral neuropathy.
Enokizumab
go.drugbank.com/drugs/DB05555InvestigationalA humanized immunoglobulin G1k anti-interleukin-9 mAb.
Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target.
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
Teverelix
go.drugbank.com/drugs/DB05624InvestigationalA synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.
International brands: Teverelix LASodium stibogluconate
go.drugbank.com/drugs/DB05630ApprovedInvestigationalSodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials.
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalNTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.
VTP-201227
go.drugbank.com/drugs/DB05652ExperimentalVTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.